In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, talks innovation in clinical technology and how the FDA can continue to promote its adoption.
In a recent video interview with Applied Clinical Trials, Iddo Peleg, CEO and co-founder at Yonalink, discussed the impact of recent FDA and NIH actions on clinical trials. With changes in funding and DEI initiatives, there is a need to make trials more accessible for patients. Peleg highlighted how advancements in technology could address this, not only increasing accessibility, but efficiency as well.
ACT: Looking forward, what should stakeholders be focusing on to ensure their research and studies remain effective in the current climate of clinical research?
Peleg: I think now that we see more acceptance for new technologies, I think they need to ask themselves if what they did in the last 20 years or the last 25 years is still relevant. If you want to stay relevant, you need to think if you are relevant. It's not enough to say, “I'm going to do exactly what we did, not just four years ago, 10 years ago, and 20 years ago.” Because if we didn't change and you do clinical trials exactly the same as you did 20 years ago, something is broken. I think all the stakeholders, even the technology vendors, do you just do some type of different angle of the same technology, or do you truly want to disrupt and you truly want to bring efficiency, you want to bring innovation into clinical trials? For the stakeholders, the pharma, and CROs, they need to ask themselves if what I'm doing right now is something that can stay or I'm doing it just because someone before me did it exactly the same. This is a time for change, this is a time for disruption. If I may say, I hope that in the next few years, we will see the FDA starting to promote more efficiency and more adaptation of new technologies. This is the key. If we have more technologies, we will have more clinical trials, we will enroll more patients, and eventually we will have more new therapies in the market, and we can make clinical trials the care option for any American.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.